16 results about "Gut microbiome" patented technology

Orally administered compositions comprising triacetin are presented that increase the concentration of short chain fatty acids in the gut, namely acetic acid, wherein the compositions comprising triacetin are palatable at desirable concentrations. The triacetin formulations can also be orally administered to a dysbiotic subject to increase short chain fatty acid (SCFA) concentrations in the gut of the subject while substantially avoiding gas production in the subject. Advantageously, administration of contemplated compositions also increases gut barrier integrity and helps restore a balanced gut microbiome.

The present disclosure relates to a use of Lacticaseibacillus rhamnosus FMBL L23004 CNN in the preparation of a medicament for preventing or treating diabetes mellitus. The Lacticaseibacillus rhamnosus FMBL L23004 CNN was deposited with the China Center for Type Culture Collection (CCTCC) on 26 Jun. 2023 under the accession number CCTCC NO: M 20231099. The Lacticaseibacillus rhamnosus FMBL L23004 CNN strain has the effect of inhibiting the activity of α-glucosidase, α-amylase, and dipeptidyl peptidase IV. Administration of the strain can significantly lower oral glucose tolerance and insulin tolerance in Type 2 Diabetes Mellitus (T2DM) mice, reduce abnormal postprandial blood glucose fluctuations, decrease fasting blood glucose levels, lower fasting insulin levels, reduce blood lipid levels, and alleviate insulin resistance. The strain significantly improves the composition of the gut microbiome, increases the abundance and diversity of beneficial gut bacteria, and reduces the relative abundance of pathogenic bacteria.

A composition contains a combination of at least one fiber and at least one probiotic and is formulated for administration to a subject in a condition of challenged gut microbiome such that the combination of at least one fiber and at least one probiotic improves and / or maintains optimal cholesterol levels in a subject in a condition of challenged gut microbiome. Preferably the subject is experiencing a microbiome stressor, such as one or more of a dietary stressor, antibiotic, other medications, infections, intense exercise, stress, alcohol, travel and combinations thereof; more preferably at least a dietary stressor; most preferably at least a high fat diet, such as a Western high fat diet or a ketogenic diet. The method can achieve at least one result that is improving and / or maintaining optimal cholesterol levels in a subject in a condition of challenged gut microbiome.

The present disclosure relates to a device for collecting gastrointestinal fluids / particles or samples. The present disclosure also relates to a process of collecting gastrointestinal fluids / particles or samples by the ingestible device. The ingestible device of the present disclosure is designed to non-invasively collect gastrointestinal particles, including biomolecules and components of the residing gut microbiome, with precise spatial resolution along the gastrointestinal (GI) tract. Upon deployment, the device's design and / or actuation mechanism facilitates the capture of gastrointestinal fluids and associated particles within those fluids. These samples are securely stored within the device until its natural egestion, after which the collected material can be subjected to further bio / chemical analyses.

The disclosure provides a computer-implemented method and system for detecting microbiome age of a subject. The method comprises obtaining a microbiota species profile from a fecal sample of the subject; predicting a gut microbiome and thus, gut health status as a value on a scale from diseased microbiome to healthy microbiome using a first machine learning model; in case the gut microbiome health status value is above a threshold, further predicting a microbiome age of the subject's gut microbiome using a second machine learning model; and providing a personalized report based on the gut microbiome health status value and, in case the gut microbiome health status value is above the threshold, a comparison between the microbiome age and the subject's chronological age.

The present invention relates to bacterial probiotics useful in aquaculture. Specifically, it discloses a selection of non-hemolytic, proteolytic, stress-tolerant bacterial strains with enhanced quorum- quenching capabilities. Moreover, the method allows detection of novel species of bacteria whose probiotic attributes could be massive for aquaculture. From the isolated bacteria, selected species were tested for their probiotic efficacy in Nile tilapia (Oreochromis niloticus), a key fish species in global finfish aquaculture. The species demonstrated significant efficacy in improving the health and growth performance of Nile tilapia juveniles. Specific growth rates and weight gain, and improved feed conversion ratios without adverse effects on fish health were observed. The gut microbiome was positively influenced by promoting beneficial bacteria while reducing harmful (opportunistic) species, leading to improved immune modulation. Survival rates were significantly boosted during a pathogenic challenge, and key immune genes were upregulated, indicating stronger local immune defenses. These findings show that the selected probiotic species offer substantial benefits for growth, feed efficiency, and disease resistance, emphasizing their potential for widespread application as probiotics in aquaculture.

Methods comprising obtaining a biological sample and extracting nucleic acids from it are disclosed. The methods process the nucleic acids for DNA sequencing and identify in the DNA sequencing data a plurality of amplicon sequence variants (ASV). The methods record the relative abundance of each ASV and classify, using a machine learning algorithm, each ASV according to one of a set of taxonomies. The set of taxonomies includes a pathobiont bacteria subset consisting of genus level groups Eggerthella group, Ruminococcus torques group, Ruminococcus gnavus group, Coprobacillus group, Streptococcus group, Bilophila group, Actinomyces group, Desulfovibrio group, Atopobiaceae group, Veillonella group, Enterococcus group, Escherichia-Shigella group, Campylobacter group, Enterobacteriaceae group, and Fusobacterium group. Based on the relative abundance of the ASV classified as pathobiont bacteria, a numerical indication of the health of the subject is calculated. Based on the numerical indication, the methods deliver to the subject a customized intervention.

The present disclosure is related to ex vivo methods and devices for identifying a presence of or predicting a risk for a condition in a subject, wherein the risk or condition is correlated with an oxidation-redox potential (ORP) of a biological sample obtained from the subject, such as a fecal sample. The methods and devices of the present disclosure can be used to diagnose and monitor gut microbiome health and assess the risk and / or presence of conditions such as obesity, metabolic dysfunction associated steatotic liver disease (MASLD), type 2 diabetes, hyperlipidemia, hypertension, cardiovascular disease, a gut specific condition, irritable bowel syndrome, an inflammatory bowel disease, ulcerative colitis, Crohn's disease, a Clostridium difficile infection, or any combination thereof based on an ORP of the subject's sample.

The technical field relates to methods for promoting gut microbiome health using low G+C Directed (LDN) analogs. More particularly, the technical field relates to methods of using LDN analogs as inhibitors of DNA Polymerase IIIC (DNA pol IIIC) enzyme to selectively reduce physiologically harmful Gram-positive bacteria with a genome having low amounts of Guanine and Cytosine (rather the genomes comprise a greater amount of adenine and thymine / uracil nucleotides) in the gut microbiome while simultaneously maintaining or increasing the proportions of beneficial microflora.

The present invention provides methods for inducing a formula-fed infant's gut microbiome trajectory to converge with that of a reference gut microbiome trajectory obtained from human milk-fed infants, the methods comprising administering an effective amount of a mixture of human milk oligosaccharides (HMOs) to the formula-fed infant. The present invention also provides methods for determining the gut maturation status of a formula-fed infant, the methods comprising providing a reference gut microbiome trajectory obtained from human milk-fed infants.

The present disclosure provides methods for enhancing the immunogenicity of a poorly immunogenic antigen-specific vaccine as well as methods for promoting diversification of the gut microbiome in a subject in need thereof comprising administering to the subject an effective amount of a beta-glucan extract derived from yeast. Kits for use in practicing the methods are also provided.

The present invention relates to the field of therapeutics and, more in particular, to pharmaceutical compositions for the prevention and / or treatment of bacterial infections and antibacterial-induced dysfunctions. The compositions of the present invention demonstrate high species-specificity in inhibiting the growth of a small number of bacterial species, and most importantly are effective also against multi drug resistant (MDR) clinical isolate species. Interestingly, one of those combinations pairs a non-antibiotic drug, vanillin, with an antibiotic drug, spectinomycin, to demonstrate a surprisingly strong inhibitory effect on the growth of clinically relevant Gram-negative pathogenic and multi-drug resistant E. coli isolates. A second set of compounds combines the polymyxin colistin with loperamide, a rifamycin, or a macrolide. Importantly, this invention relates to combinations that enable narrow-spectrum antibacterial therapies, constituting a major effort of current and future drug development efforts in order to prevent major side effects of antibacterial strategies. This invention also relates to pharmaceutical combinations useful to prevent an adverse effect on the gut microbiome, induced by the use of antibacterial compounds.

This invention discloses a binary classification method for predicting immunotherapy response in colorectal cancer patients based on gut microbiome metagenomic data. The method includes the following steps: acquiring metagenomic sequencing data and immunotherapy response records from colorectal cancer patients; performing quality control, host removal, species and function annotation on the sequencing data to generate a microbial abundance matrix and a relative abundance spectrum of functional genes; integrating multi-source data to construct an initial feature dataset; constructing a microbial interaction network based on this dataset, and using a multi-stage feature selection strategy to select key features to form a final feature dataset; obtaining support vector machine (SVM) binary classification results for predicting immunotherapy response based on this dataset, and evaluating model performance using a cross-validation framework. This technical solution constructs a more stable feature dataset and ensures that the constructed classification model possesses both high accuracy in predicting immunotherapy response in colorectal cancer patients and good biological interpretability.

The present invention provides compositions, systems, and methods for treating or preventing brain disorder with compositions comprising a prebiotic (e.g., green banana flour) and one or both of Lactobacillus reuteri, and Lactobacillus plantarum. In certain embodiments, the brain disorder is selected from neuroinflammation, a neurological disorder, a neuropsychiatric disorder, and a behavioral disorder. In some embodiments, the prebiotic, Lactobacillus reuteri, and Lactobacillus plantarum are provided as a powder inside an ingestible capsule.

The present invention belongs to the technical field of plant extraction. Disclosed are a medium-chain inulin, a preparation method therefor, and the use thereof. The unique inulin structure and chain length disclosed in the present invention reshape the gut microbiome and metabolome, and in particular, selectively modulate key microorganisms such as Faecalibacterium, Bifidobacterium, Parabacteroides, Clostridium_sensu_stricto_1 and Akkermansia, and metabolites such as nicotinamide, taurocholic acid, aldosterone, corticosterone, 2-(1H-indol-3-yl)acetic acid, 5-hydroxy-L-tryptophan, 5α-DHT and maltose, thereby promoting the amelioration of obesity and the improvement of the overall health of a host. The core microorganisms and metabolites identified by the technical solution represent potential therapeutic targets for preventing or treating obesity and related metabolic symptoms. These findings support the development of inulin-based nutritional strategies to effectively manage body weight by modulating specific microbiota and the metabolome.

This invention relates to microbiome markers for healthy aging. There is provided, inter alia, a method of predicting or determining healthy aging in an individual, the method comprising: (a) determining the presence or an amount of at least one microorganism in a sample representing the individual's gut microbiome, wherein the at least one microorganism is selected from Table 1A, wherein an enrichment of said microorganisms is indicative of healthy aging; and / or (b) determining the presence or an amount of at least one microorganism in a sample representing the individual's gut microbiome, wherein the at least one microorganism is selected from Table 1 B, wherein a depletion of said microorganisms is indicative of healthy aging.